Mylan Fourth Quarter 2013 Adjusted Diluted EPS Increases 20% to $0.78 and Full Year Adjusted Diluted EPS Increases 12% to $2.89
Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes
Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial
Ventana Medical Systems, Inc., Convenes International Patient Safety Advisory Board To Advance Standard Of Care And Reduce Risk Of Misdiagnosis
TUCSON, Ariz., Feb. 25, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc.
NICE recommendation set to leave patients with newly diagnosed advanced melanoma without access to Yervoy® (ipilimumab)
Deal Provides Elanco with a Leading Poultry Vaccine Portfolio and Manufacturing Capabilities